SGLT2 drugs for Chronic Kidney Disease

6 tracked SGLT2 drugs in the Chronic Kidney Disease race. The class explanation lives on the SGLT2 page; the full indication pipeline across every mechanism is on the Chronic Kidney Disease page.

3 approved / phase 42 Phase 31 preclinical / unstaged

Head-to-head evidence: Canagliflozin vs Dapagliflozin · Canagliflozin vs Empagliflozin · Canagliflozin vs Enavogliflozin · Canagliflozin vs Zibotentan + Dapagliflozin · Canagliflozin vs janagliflozin · Dapagliflozin vs Empagliflozin

The roster

← all SGLT2 drugs